... for a 1.25 credit.
Comments: Rolling out the short call aspect of my XBI covered call at ~50% max to the June expiry for a 1.25 credit.
Cost basis now 85.94 (See Post Below) minus 1.25 or 84.69.
XBI is pushing back into strong resistance in the range on 96.5 - 100.
Looking for a higher high with momentum divergence to setup another round of weakness.
Biotech is still near its Covid lows.
This etf is about to test a key level.
Expecting a bounce here, lets see.
$ 87.87 - 88.99 is the immediate support.
$ 79.23 - 80.50 is the next strongest support.
$ 93.15 - 93.21 the first major resistance above.
===========================================
... for a 1.90 credit.
Comments: Selling a put here, since the resulting cost basis if assigned shares would be lower than the cost basis of the position I've currently got on now. The full position is now a June 21st 82/88 covered strangle (i.e., short put, stock, short call).
Will look to take profit at 50% max.
Metrics:
Buying Power Effect/Break Even/Cost...
... for an 85.94 debit.
Comments: 32.5% 30-Day IV. Buying a one lot and selling a -75 delta call against to emulate a 25 short put, take advantage of call side IV skew, and to have built-in defense via the short call.
Metrics:
Cost Basis/Break Even/Buying Power Effect: 85.94
Delta/Theta: 28.5/4.31
Max Profit: 2.06 ($206)
ROC at Max: 2.40%
ROC at 50% Max:...
XBI appears to be indicating signs of bottoming out, with a potential target range of 103/104 by the end of April 2024, provided that the 92/95 range holds as support.
Biotechnology is expected to be a hot subsector this year as healthcare recovered further from
the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for
diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend
with XBI pivoting to bullish back in early November. I add long positions when I...
AMEX:XBI Formed a flat base from early January to late February before breaking out. You can see on this chart it is either a failed break-out (with more downside to go) or it is retesting that breakout area and will soon resume its upward trend. All TBD.
In addition to coming down to the breakout area it looks like it “may” be getting support at the 50 DMA...
XBI just recently broke out of a major range and is now on its way to retake the 200 wk moving average. With many biotechs breaking out of early bases, XBI looks likely to break to the upside.
... for an 81.63 debit.
Comments: 32.1% 30-Day IV.
My general preference for ETF IV is >35%, but there isn't much currently there in my ETF screener, and I'm already in a GDX position: TQQQ (52.3%); USO (38.1%); GDXJ (35.0%).
Buying a one lot and selling the -75 delta call against to emulate a 25 delta short put with "built-in" defense of the position via...
XBI, the S&Ps Biotech ETF has been ranging nicely just below a major pivot that has acted as resistance for over two years. Bounced off the 20 EMA on the daily and made a beautiful candle on Friday. Anything that happens below $95 must be taken with a grain of salt, but it looks like it wants to breakout and flip that resistance pivot to support.
... for a 74.27 debit.
Comments: Adding a "rung" to my XBI position here .... . Selling the -75 delta call and buying a one lot to emulate a 25 short put to take advantage of IV skew in calls (40.2% at the 77 strike on the call side; 33.0% on the put).
2.73 max profit on BPE of 74.27; 3.68% ROC as a function of BPE at max; 1.84% at 50% max.
Both biotech ETF's AMEX:XBI and NASDAQ:IBB are showing tremendous weakness in the face of a strong market. I suspect that when the market is ready to pullback it may take this a little lower especially in the face of a strong TVC:DXY / Dollar Index. Good luck traders!
AMEX:XBI is giving long term buy signals as the chart displays. Super trend signals a buy, also MACD and KST crossovers confirm trend direction.
XBI is a somewhat volatile bio-tech ETF.
This ETF is also great for selling options on when volatility is high, as the premium you receive is often much higher than employing the strategy on SPY.
Here...
